Background: HCV is the main causative agent of chronic liver disease, which could progress to liver cirrhosis and hepatocellular carcinoma. By using a recently developed genome-length HCV RNA replication reporter assay system, we found that hydroxyurea (HU), an inhibitor of DNA synthesis, inhibited HCV RNA replication. Methods: To test the hypothesis that HU suppresses HCV replication in humans, we conducted a Phase I trial involving Japanese patients with chronic hepatitis C (CHC) and investigated the safety and effectiveness of a 4-week course of oral HU.
HCV is the main causative agent of chronic hepatitis C (CHC), which can progress to liver cirrhosis or hepatocellular carcinoma [1] [2] [3] . HCV infection is a global health problem with >170 million individuals infected worldwide [4] . HCV genotype 1 is the major genotype found in Japan, the United States and many other countries. Unfortunately, <50% of the patients infected with HCV genotype 1 respond to the standard combination therapy of pegylated interferon (PEG-IFN) and ribavirin [5, 6] .
In order to develop a more effective therapy, especially for genotype-1-infected patients, we recently developed a genome-length HCV RNA (strain O of genotype 1b) replication reporter system (OR6), which has served as an effective screening tool [7, 8] . By application of this system, we found that hydroxyurea (HU), an inhibitor of DNA synthesis, inhibited HCV RNA replication [9] . Furthermore, HU is an inhibitor of the enzyme ribonucleoside diphosphate reductase, which is involved in DNA synthesis and exerts cytostatic effects via this mechanism. HU is primarily used to treat patients with chronic leukaemia, melanoma and other solid tumours [10] . In addition, HU activity against viruses such as HIV and herpes simplex virus (HSV) has been recently reported [11, 12] . Several clinical trials of HU in combination with a protease inhibitor have been performed in HIV-infected patients [10, 13] . In these studies, the HU dose levels were set between 500 mg once daily and 400 mg three times daily. Moreover, in humans, the maximum tolerated dose (MTD) of HU was estimated as 800 mg/m 2 when administered orally every 4 h; at this dose, the mean peak plasma concentration increased to 2,480 µmol/l [14] . The MTD of HU is substantially higher than its 
Introduction
50% effective concentration (EC 50 ), which was determined in our previous study [9] ; thus, these observations prompted us to conduct a Phase I clinical trial of HU in CHC patients. This is the first report on the anti-HCV activity of HU in CHC patients.
Methods

Patients
From January 2009 to March 2009, nine Japanese CHC patients (one male and eight female, mean age 64 years [range 59-71]) were enrolled in the trial. These patients, who satisfied the inclusion criteria, were recruited from the outpatient Hepatitis Clinic, Yokohama City University Medical Center (Yokohama, Japan; Table 1 ). According to the inclusion criteria, the patients were required to have the following haematological laboratory values at entry: absolute neutrophil count >1,500 cells/µl, absolute platelet count >70,000 cells/µl and haemoglobin >10.0 g/dl. The following patients were excluded: lactating or pregnant patients and those with unstable angina pectoris, cardiac insufficiency (New York Heart Association Classes III and IV), uncontrolled arrhythmia, uncontrolled hypertension and uncontrolled diabetes mellitus at the time of acquisition of consent. HCV RNA was detected in the serum of all the patients at 6 months of follow-up or later. Six patients had previously received the standard combination therapy of PEG-IFN-α2b and ribavirin, and one patient had received IFN monotherapy; however, none of these patients showed response to treatment. The remaining two patients had refused IFN treatment. HCV genotype analyses revealed that all the patients were infected with HCV genotype 1b.
None of the patients had previously received corticosteroid or immunosuppressive treatment. Furthermore, none of the patients had a history of alcohol or drug abuse, and there was no evidence of any metabolic or autoimmune disorders. The trial was approved by the institutional Ethics Committee (Yokohama City University Medical Center) and complied with the guidelines of Good Clinical Practice, the Helsinki Declaration and Japanese laws. Informed consent was obtained from all the patients.
Study design
We conducted a Phase I study to investigate the safety and effectiveness of a 4-week course of oral HU in order to determine the recommended dose (RD) for a subsequent Phase II study. The primary aim was to evaluate the safety of HU by determining the RD; this was performed by sequential monitoring of toxicity in three patients in each cohort. The secondary aim was to assess the anti-HCV effect of HU. One cycle consisted of consecutive oral administration of HU (Hydrea ® ; Bristol-Myers Squibb, Tokyo, Japan) for 28 days followed by an observation period. The HU dose levels were set between 500 mg once daily and 500 mg four times daily, with a starting dose of 500 mg three times daily because these dose levels were previously reported for patients with sickle cell anaemia [15] . Any Grade 4 haematological toxicity and Grade 3 non-haematological toxicity observed at any point during the therapy was considered as dose-limiting toxicity (DLT). The criteria for dose deescalation were as follows: absolute neutrophil count <750 cells/µl, absolute leukocyte count <1,500 cells/ µl and absolute platelet count <50,000 cells/µl during the therapy. The toxicity was assessed according to the Common Terminology Criteria for Adverse Effects (CTCAE) version 3.0 (Public Health Service, National Institutes of Health, National Cancer Institute, Bethesda, MD, USA).
DLT data were continually monitored to enable decisions regarding HU dose escalation and de-escalation based on a new dose-finding algorithm using a Bayesian study monitoring method [16, 17] .
Laboratory measurements
Blood tests, including measurement of serum alanine aminotransferase (ALT) and HCV RNA concentrations, were performed immediately before the treatment, every week during the treatment and 4 weeks after cessation of the HU treatment. The serum HCV RNA levels including stored serum during prior IFN and PEG-IFN therapy were measured using the TaqMan ® PCR assay (COBAS ® TaqMan ® HCV test; Roche Diagnostics, Tokyo, Japan; Table 1 ). The serum ALT concentrations and other parameters were measured using a sequential multiple autoanalyser.
Results
A total of nine patients were treated with an HU dose level of 500 mg three times daily. DLT was not observed at this dose level; however, two patients (number 5 and number 6) required dose de-escalation at 3 weeks after therapy initiation because they developed Grade 3 neutropaenia. After dose de-escalation, their neutropaenia resolved at 4 weeks after therapy initiation ( Figure 1A) . For all nine patients, dose escalation was not performed according to the clinical judgement of the investigators because two patients experienced adverse events (AEs), the levels of which were close to Grade 4; thus, 500 mg three times daily of HU was estimated to be an acceptable dose. Discontinuation of treatment was not required for any of the patients. All the patients experienced ≥1 treatment-related AEs. The most frequently observed treatment-related AE was neutropaenia, which was observed in all 9 (100%) patients ( Figure 1A) , followed by leukopaenia ( Figure 1B ) and thrombopaenia ( Figure  1C ), each in 6 (67%) patients, and brown discolouration of the nails in 4 (44%) patients. Most of these treatmentrelated AEs were CTCAE Grade 1 or 2, except neutropaenia, which was Grade 2 or 3; however, severe AEs were not observed. Furthermore, a decrease in serum HCV RNA concentrations during HU treatment was apparent in eight of the nine patients ( Figure 1D) ; however, the decreases were modest and were not statistically significant. In patient 9, the maximum decrease in the serum HCV RNA concentration was -0.44 log 10 IU/ml at 4 weeks after therapy initiation, and the mean decrease in the serum HCV RNA concentration at the end of the treatment was -0.12 log 10 IU/ml. A reduction in HCV RNA levels up to nadir levels was achieved in eight patients (median -0.27 log 10 IU/ml [range -0.08--0.44]) at various times during the 4 weeks after therapy initiation ( Figure 1D ). The serum HCV RNA concentration increased in six of the nine patients at 4 weeks after cessation of the HU treatment; however, significant changes in the serum ALT concentrations during this trial were not observed in any of the patients ( Figure 1E ).
Discussion
HU is an inhibitor of the enzyme ribonucleoside diphosphate reductase that catalyses the conversion of ribonucleotides to deoxyribonucleotides, which are used during DNA synthesis. For decades, HU has been used as an anti-neoplastic agent for the treatment of patients with chronic granulocytic leukaemia and several types of cancers [10] . Currently, it is used to treat patients with leukaemia and other malignancies, such as sickle-cell anaemia, HIV infection, thrombocythaemia and psoriasis [18] . Recently, by using the OR6 system, we found that HU effectively inhibited HCV RNA replication. The median EC 50 of HU (60 µmol/l with a 50% cytotoxic dose of 150-200 µmol/l) was considerably lower than the clinically achievable concentration (approximately 2,480 µmol/l) [9] . Furthermore, in this trial, the mean plasma concentration of HU was estimated as 272-990 µmol/l, as previously reported [14] . In this trial, we have shown, for the first time, that oral HU treatment might be associated with a decrease in the serum HCV concentration. These results strongly suggest that HU exhibits antiviral activity in patients with CHC infection. However, CTCAE Grade 3 neutropaenia was observed during this 4-week trial; therefore, reduction in the HU dose is required for longer treatment periods.
HU is thought to reduce serum HCV RNA concentration in CHC patients via two distinct mechanisms. The first mechanism, which has been reported for HUinduced HIV inhibition, involves prevention of G1/S transition by HU, which could play an important role in HCV inhibition [19, 20] . Recently, cyclophilin B, a host factor, was identified as a crucial factor for the efficient replication of the HCV genome [21] ; however, other unidentified host factors could also be crucial in this regard. The second mechanism might be that in which HU inhibits HCV RNA replication by interacting with these important host factors. Drugs that target such host cellular factors instead of the virus are less likely to induce drug resistance in HCV. Although the anti-HCV activity of HU alone might not be satisfactory in this trial, HU could be considered as a component of a new combination therapy involving IFN-α or other anti-HCV agents, such as ribavirin, protease inhibitors and polymerase inhibitors for CHC patients. Indeed, ribavirin, a cornerstone of the current standard therapy, alone did not exhibit sufficient anti-HCV activity, as previously reported [22, 23] .
In conclusion, this Phase I trial revealed that HU suppresses HCV replication in CHC patients. Further clinical trials including a new combination therapy involving IFN-α or other anti-HCV agents should clarify whether HU is a potential anti-HCV agent that will be effective for the treatment of CHC patients.
